Article Text

Download PDFPDF
Endoscopic resection for oesophageal mucosal adenocarcinoma
  1. Philip Hendy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Endoscopic therapy should be the standard of care for OmAC

This prospective study,1 by some margin the largest of its kind, demonstrates emphatically the safety and efficacy of endoscopic therapy for Barrett's oesophageal mucosal adenocarcinoma (OmAC).

The association between Barrett's oesophagus (BO) and oesophageal cancer has been recognised since the 1970s. Treatment options for Barrett's neoplastic lesions include surgical oesophageal resection, endoscopic resection (ER) alone and ER combined with ablative therapy. Society guidelines exhibit variance with regard to management of OmAC. Furthermore, data are limited to small studies, with short follow-up, with high grade dysplasia (HGD) and OmAC included as one entity. This study aimed to clarify the safety and efficacy of endoscopic therapy for OmAC and to investigate the associations of treatment failure.

Data were collected prospectively from all patients referred to a single tertiary …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.